Lithuania
Tuberculosis profile
| High MDR-TB burden |
Population  2013 3 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.25 (0.25–0.26) 8.4 (8.4–8.5)
Mortality (HIV+TB only) 0.022 (<0.01–0.04) 0.73 (0.31–1.3)
Prevalence  (includes HIV+TB) 2.6 (1.2–4.5) 85 (39–148)
Incidence  (includes HIV+TB) 2 (1.8–2.2) 65 (61–72)
Incidence (HIV+TB only) 0.097 (0.021–0.17) 3.2 (0.7–5.8)
Case detection, all forms (%) 80 (73–86)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 11 (9.5–14) 44 (39–49)
MDR-TB cases among notified pulmonary
TB cases
140 (120–170) 130 (120–150)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 009   174
Pulmonary, clinically diagnosed 250   0
Extrapulmonary 134   6
       
Total new and relapse 1 573    
Previously treated, excluding relapses 132    
Total cases notified 1 705    
Among 1 573 new and relapse cases:
37 (2%) cases aged under 15 years; male:female ratio: 2.6
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 039 (103%) 312 (100%) 1 354
Laboratory-confirmed RR-/MDR-TB cases     273
Patients started on MDR-TB treatment     256
TB/HIV 2013 Number (%)
TB patients with known HIV status 1 143 (67)
HIV-positive TB patients 39 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 80
Previously treated cases, excluding relapse, registered in 2012 57
HIV-positive TB cases, all types, registered in 2012 58
RR-/MDR-TB cases started on second-line treatment in 2011 43
XDR-TB cases started on second-line treatment in 2011 0
Laboratories 2013  
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 10.1
Drug susceptibility testing (per 5 million population) 10.1
Sites performing Xpert MTB/RIF 8
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-29 Data: www.who.int/tb/data